Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
ViiV Healthcare
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Men and non-pregnant women with chronic HIV-1 infection
Antiretroviral-experienced with documented historical or baseline resistance, intolerability, and/or contraindications to antiretrovirals in at least three classes
Failing current antiretroviral regimen with a confirmed plasma HIV-1 RNA ≥ 400 c/mL (first value from Investigator, second from Screening labs)
Must have ≤ 2 classes with at least 1 but no more than 2 fully-active antiretrovirals remaining which can be effectively combined to form a viable new regimen, based on current and/or documented historical resistance testing and tolerability and safety
Able to receive ≥ 1 fully active approved antiretroviral as part of the OBT from Day 9 onwards in the Randomized Cohort
Subjects without any remaining fully active approved antiretroviral may be enrolled in the Non-Randomized Cohort
You may not be if
Chronic untreated Hepatitis B virus (HBV) (however, patients with chronic treated HBV are eligible)
HIV-2 infection
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 7 x ULN
Alkaline Phosphatase \> 5 x ULN
Bilirubin ≥ 1.5 x Upper limit of normal (ULN) (unless subject is currently on atazanavir and has predominantly unconjugated hyperbilirubinemia)
Clareo Health | Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
